Immunomic Therapeutics Appoints Andrew Eisen, M.D., Ph.D. As VP, Clinical Development

Published on :

Immunomic Therapeutics Appoints Andrew Eisen, M.D., Ph.D. As VP, Clinical Development ROCKVILLE, Md.–(BUSINESS WIRE)–Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today the appointment of Andrew Eisen, M.D., Ph.D. as VP, Clinical Development. Dr. Eisen is a translational medicine and clinical development specialist with over 20 years of experience in the biotech [….]

BrainScope Advances its Commercial Adoption and Appoints Industry Veteran Susan Hertzberg as CEO

Published on :

BETHESDA, MD. June 24, 2019 – BrainScope announced today the appointment of Susan Hertzberg as Chief Executive Officer.  This is the 4th equity-backed venture that Hertzberg will helm.  She is a proven commercial stage leader with an impressive track record of bringing innovative products and services to market and profitably scaling and delivering exceptional market [….]

Immunomic Therapeutics Announces Promotion of Teri Heiland, Ph.D. to Chief Scientific Officer

Published on :

Immunomic Therapeutics Announces Promotion of Teri Heiland, Ph.D. to Chief Scientific Officer June 20, 2019 04:05 PM Eastern Daylight Time ROCKVILLE, Md.–(BUSINESS WIRE)–Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today the promotion of Teri Heiland, Ph.D. to Chief Scientific Officer. In her new role, Dr. Heiland will oversee all of research [….]

Paragon Bioservices Strengthens its Commitment to World Class GMP Viral Therapy Manufacturing with the Appointment of Two Key Leadership Positions and Advanced Commitment to Quality

Paragon BioBuzz People on the Move
Published on :

Paragon Bioservices Strengthens its Commitment to World Class GMP Viral Therapy Manufacturing with the Appointment of Two Key Leadership Positions and Advanced Commitment to Quality John R. Mosack to head Paragon’s GMP Manufacturing at its Baltimore CampusAdam Sachs to lead Program Management and Strategic Client AllianceDeborah Wild promoted to Chief Quality and Regulatory Affairs Officer [….]